Our results provide evidence that combinatorial OncoAd and ICB therapy significantly enhanced the anti‐tumor efficacy of anti‐PD‐1 by increasing CD8+ T cell infiltration and reducing the tumor volume in CRC. Here, CD8A is linked to neoplasm.